Tom Metz

Metz has 18 years experience in the development and application of high throughput mass spectrometry-based proteomics, metabolomics and lipidomics methods in systems biology studies of chronic and infectious disease using EMSL capabilities. His research involves biomarker discovery, as well as studies to identify the roles that molecules play in promoting or resolving disease. More recent studies focus on developing methods to identify novel, bioactive molecules in microbial communities. Metz is serving a three-year term on the User Executive Committee, which will end in 2023.